Press Releases

Nov 07, 2023

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

Read More

Nov 02, 2023

Veracyte to Participate in the Stephens Annual Investment Conference

Read More

Oct 27, 2023

Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development

Read More

Oct 19, 2023

C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe

Read More

Oct 18, 2023

C2i Genomics and Gustave Roussy Collaborate to Demonstrate Utility of ctDNA-guided Immunotherapy in Early-Stage Solid Tumors

Read More

Oct 17, 2023

Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023

Read More

Oct 12, 2023

New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease

Read More

Oct 04, 2023

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier

Read More

Sep 28, 2023

New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

Read More

Sep 28, 2023

Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023

Read More